Articles On Antisense Therapeutics (ASX:ANP)

Several ASX healthcare companies have upcoming catalysts, which can be a focal point for healthcare investors Dimerix forecasts the second interim analysis of its ACTION 3 global phase III trial of DMX-200 to treat FSGS in around mid-CY25...

What’s in a name? Not much, according to the CEO of the now cashed-up Percheron, Dr James Garner. Formerly known as Antisense Therapeutics, the rare disease specialist changed its name to Percheron in January. Percheron means ‘draught horse...

Nyrada to launch phase I first-in-human trial after passing preclinical safety studies Neuren Pharmaceuticals ‘mini me’ Percheron seeks funds for rare disease program Another win for Pro Medicus, this time locally   Nyrada (ASX:NYR) share...

Stockhead joined with IR Department and Morgans for HealthInvest 2024 in Sydney last week The event highlighted some of ASX’s leading and up-and-coming biotech and life sciences companies Imricor Medical Systems, Race Oncology, Clarity Pha...

Australia’s clinical trials sector generated $1.6bn for the nation’s economy in 2022 according to MTPConnect PharmAust is currently undertaking a Phase 1 open label extension study at two sites in Australia Dimerix has seven Australian sit...

ASX health stocks dropped 1.22% in the past four days, while the broader markets fell 1.35% Morgans downgrades Ramsay Health Care following its FY24 results, believes a ‘near-term earnings recovery looks challenging’ Percheron reports posi...

Stockhead joins with IR Department and Morgans for HealthInvest 2024 in Sydney in September Event to highlight some of ASX’s leading up-and-coming health and life sciences companies Clarity Pharmaceuticals, Percheron Therapeutics, Imricor,...

ASX health stocks fall in past five days in line with broader markets as investors spooked by hotter than expected inflation Dimerix up 33% for week after inking second exclusive license deal for commercialisation of its Phase 3 kidney dis...

Percheron could double if clinical goes well But Taylor Collison admits that PER is a speculative investment Probiotec meanwhile offers a resilient business model, says Sequoia   Perceheron could double after trial readout at year-end Tay...

BlinkLab becomes first healthcare sector IPO for 2024 with chair Brian Leedman hoping to replicate ResApp success Percheron Therapeutics still to finalise recruitment of Phase 2B trial but remains confident of results in CY24 Clarity Pharm...

Morgans says economic challenges have been catalyst for innovation and resilience in ASX health sector PharmAust submits supplementary data to US FDA from Phase 1 MEND study in support of its ODD request Singular health gets $1 million bac...

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.20% to 7,073.20. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spoti...

ASX health stocks rise in past five days and outpace broader markets Blue chip ResMed slips as US FDA approves weight loss drug Clinical stage immuno-oncology small cap Immutep gains 160%  Morgans healthcare and life sciences expert Iain...

US FDA requested Botanix to change its instructions paper Antisense says ATL1102 could be effective in muscular dystrophy Actinogen changes Phase 2b design to reduce cost and time to initial results   Botanix plunges after receiving FDA f...

2023 a case of “haves and have nots” for ASX biotech sector as companies with good catalysts lead the pack  Neuren’s results of Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome due in December Antisense Therapeutics Phase2b t...

  Dr James Garner – Managing Director – Antisense Therapeutics (ASX:ANP) is a biotechnology company, developing and commercialising Antisense pharmaceuticals for large unmet markets in rare diseases.

ASX health sector rises in line with broader markets as reporting season comes to end EBR Systems on schedule for key US FDA submission in Q1 CY24 for (WiSE) CRT system Health imaging company Mach7 achieves record sales order book of $40.3...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ANP)) - Antisense Therapeutics ((APM)) - APM Human Services International ((ANG)) - Austin Engineering ((CDA)) - Codan ((DBI)) - Dalrymple Bay Infrastructure ((DGL)) - D...

Futures indicate the ASX is set to open lower as the new week begins, following a relatively flat close on Wall Street at the end of last week. Uncertainty looms over China’s economic prospects, exacerbated by the news of Evergrande Grou...

Rio Tinto's (ASX:RIO) half-year profit fell 34% due to weaker commodity prices. The $US5.7 billion underlying result and dividend missed analyst estimates. Australian iron ore dominated the result, but lower prices offset improved volumes....

26 Jul 2023 - A snapshot of the stocks on the move, featuring QX Resources (ASX:QXR), Antisense Therapeutics (ASX:ANP) and West Wits Mining (ASX:WWI).

The June quarter headline inflation came in at 6 per cent, lower than the expected 6.2 per cent. Similarly, the trimmed mean inflation, which excludes volatile food and energy costs, eased to 5.9 per cent, below the expected 6 per cent. On...

  QX Resources (ASX:QXR) announced that discussions and due diligence have advanced on the Liberty Lithium Brine Project in the California, USA. Commenting on this announcement, CEO, stephen prominitz stated, “Ongoing studies, detailed due...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

Avita Medical receives US FDA premarket approval for its RECELL System to treat vitiligo Telix will buy UK medical device firm Lightpoint Medical and its radio-guided surgery business SENSEI Antisense in strong position with new CEO, forme...

ShareCafeTech and Real Estate weigh on market: ASX closes 0.26% lower by Peter Milios   At the closing bell, the S&P/ASX 200 was 0.26 per cent lower at 7,099.70. The drop was mainly driven by losses in the technology and real estate sec...

ShareCafeBond yields surge: ASX 0.09% lower at noon by Peter Milios   At noon, the S&P/ASX 200 is 0.09 per cent lower at 7,111.50, as certain sectors sensitive to interest rates declined, while commodity sectors saw gains due to rising...

Avita receives US FDA approval for RECELL Emyria and Antisense to progress trials Beamtree has won a key contract in Canada   Avita Medical (ASX:AVH) announced that the US FDA has signed off on a premarket approval (PMA) for the use of it...

ShareCafeStocks of the Hour: ICL, AVH, ANP                  Iceni Gold (ASX:ICL) has hit a high-grade vein at the Everleigh well in Western Australia. Technical Director David Nixon comments: “The high-grade rock chip results from the...

08 Jun 2023 - A snapshot of the stocks on the move featuring Iceni Gold (ASX:ICL), Avita Medical (ASX:AVH) and Antisense Therapeutics (ASX:ANP).

Futures suggest the ASX will open lower today following weak tech trading on Wall Street overnight. Elsewhere, the Bank of Canada decided to lift the nation’s cash rate to a 22-year high of 4.75 per cent overnight. Back on home soil,...

Orphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an exclusivity period for pharma companies The average orphan drug in the US retails for US$7,000 per month   Rare or ‘Orphan’ diseases affect...

Antisense Therapeutics (ASX:ANP) has announced the appointment of Dr James Garner as its new chief executive officer and managing director.

Little Green Pharma gets extended contract from the French government US FDA’s decision paves the way for a clinical involving Immuron’s drug Antisense Therapeutics announces new CEO   Cannabis stock Little Green Pharma (ASX:LGP) has been...

CardieX jumps 16pc after getting FDA clearance for CONNEQT Pulse CONNEQT Pulse is a world first multi-use vascular biometric monitor  Three ASX biotechs received clearance to commence studies   Health devices and wearables tech company Ca...

ASX health stocks fall 1.5% in the past five days, broader markets fall on global banking concerns Neuren Pharmaceuticals has soared 60% after FDA approves its drug for Rett’s syndrome  Antisense starts chronic monkey toxicology study of A...

Antisense Therapeutics (ANP) commences the dosing stage of a nine-month chronic monkey toxicology study of its ATL1102 treatment in the US The toxicology study is expected to support the advancement of ATL1102 for the potential treatment...

ShareCafeASX closes 0.18% higher ahead of Wall Streets CPI data by Peter Milios   US stock market futures were down slightly before the opening bell, as investors await the release of January CPI data. S&P 500 and Dow Jones futures were...

ShareCafeHealthcare pushes ASX 0.4% higher at noon by Peter Milios   On the back of gains from Communication Services, Information Technology and Healthcare, at noon, the S&P/ASX 200 is 0.40 per cent higher at 7,447.3. Challenger rose 5...

ShareCafeStocks of the Hour: ELT, FAL, MAT, ANP                    Elementos (ASX:ELT) announced a 2023 Mineral Resource Estimate update at its Oropesa Tin Project in Spain. The 2023 MRE increased by 4% to 19.6 million tonnes at 0.39%...

Antisense Therapeutics (ANP) receives approval to conduct its phase two trial in non-ambulant boys with Duchenne muscular dystrophy (DMD) in Turkey The approval came from the Turkish Medicines and Medical Device Agency to conduct a doubl...

14 Feb 2023 - A snapshot of the stocks on the move featuring Elementos (ASX:ELT), Falcon Metals (ASX:FAL), Matsa Resources (ASX:MAT) and Antisense Therapeutics (ASX:ANP).

Emyria surged 10% after securing MDMA supply for its therapies Antisense commences second phase animal trial Record top and bottom lines for Vitura Health   After surging 60% last week, Emyria (ASX:EMD) rose another 12% this morning after...

Antisense Therapeutics (ASX:ANP) has reported what it describes as initial positive muscle functional data from a DMD mdx animal study assessing the use of the combination of antisense to CD49d with a dystrophin exon skipping restor...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Antisense Therapeutics (ANP) reports “positive” muscle function results following the completion of its combination drug study for DMD in mouse models The study comprised six groups of eight DMD mice each and showed mice who received th...

ShareCafeASX hits highest point since April: Aus shares close 0.33% higher by Peter Milios   Australian shares rose 0.3 per cent to close at their highest since April, boosted by real estate and miners. Coal miners are mixed as UBS reports...

ShareCafeInflation has peaked: ASX 0.45% cent higher at noon by Peter Milios   The head of economic analysis at the Reserve Bank of Australia (RBA), Marion Kohler, has announced that inflation has peaked at around 8 per cent at the end of 2...

ShareCafeStocks of the Hour: PBL, AL3, ANP                    Parabellum Resources (ASX:PBL) has announced that their assay results demonstrate strong rare earth oxide mineralization. In response, Chairman Mark Hohnen commented: “We c...

01 Feb 2023 - A snapshot of the stocks on the move featuring Parabellum Resources (ASX:PBL), AML3D (ASX:AL3) and Antisense Therapeutics (ASX:ANP).